Fifth Third Bancorp’s Lifecore Biomedical LFCR Stock Holding History

Fifth Third Bancorp’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$740	Sell	141 -69	-33%	-$348	﹤0.01%	4196
2026 Q1	$781	Buy	210 +79	+60%	+$545	﹤0.01%	4151
2025 Q4	$1.07K	Hold	131	–	–	﹤0.01%	2508
2025 Q3	$964	Sell	131 -37	-22%	-$280	﹤0.01%	2532
2025 Q2	$1.36K	Buy	168 +101	+151%	+$681	﹤0.01%	2389
2025 Q1	$472	Sell	67 -63	-48%	-$392	﹤0.01%	2451
2024 Q4	$966	Sell	130 -90	-41%	-$575	﹤0.01%	2410
2024 Q3	$1.08K	Buy	+220	New	+$1.15K	﹤0.01%	2433
2020 Q3	–	Sell	-1,000	Closed	-$8K	–	2324
2020 Q2	$8K	Hold	1,000	–	–	﹤0.01%	1786
2020 Q1	$9K	Hold	1,000	–	–	﹤0.01%	1746
2019 Q4	$11K	Hold	1,000	–	–	﹤0.01%	1821
2019 Q3	$11K	Sell	1,000 -600	-38%	-$6.53K	﹤0.01%	1775
2019 Q2	$15K	Buy	+1,600	New	+$16.2K	﹤0.01%	1720

Other funds holding LFCR

Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return

325 Capital New York $419M AUM 75.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

QOP

Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Fifth Third Bancorp's LFCR Position: Q2 2026 in Review

Fifth Third Bancorp reduced its Lifecore Biomedical (LFCR) stake by 33% in Q2 2026, selling an estimated $348 and leaving 141 shares worth $740. The position accounts for ﹤0.01% of the portfolio, ranked #4196.

Fifth Third Bancorp first reported a position in LFCR in Q2 2019 and has held it in 13 quarters since. The position peaked at $15K in Q2 2019. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

Fifth Third Bancorp held 141 shares of Lifecore Biomedical worth $740 as of Q2 2026.
Fifth Third Bancorp sold 69 Lifecore Biomedical shares in Q2 2026, an estimated $348.
Lifecore Biomedical made up ﹤0.01% of Fifth Third Bancorp's portfolio in Q2 2026, its #4196 holding.
Fifth Third Bancorp first reported a position in Lifecore Biomedical in Q2 2019 and has held it in 13 quarters since.
Fifth Third Bancorp's Lifecore Biomedical position peaked at $15K in Q2 2019.
99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Fifth Third Bancorp's 13F filing for Q2 2026, filed 5 Aug 2026.